In many cancer types, cancer cells try to survive by escaping attack from the immune system. These cancer cells hijack mechanisms called immune checkpoints to trick the immune system into thinking they are healthy cells. Recent advances in cancer treatment have focused on developing immune checkpoint blockers, which have revolutionized treatment approaches for many cancer patients, including those with metastatic non-small-cell lung cancer (mNSCLC).
St. Jude Children's Research Hospital scientists have developed an integrated, high-throughput system to better understand and possibly manipulate gene expression for the treatment of disorders such as sickle cell disease and beta thalassemia. The research appears today in the journal Nature Genetics.
New York [US], September 22 (ANI): According to a study co-led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center, Harvard Medical School, and Dana-Farber Cancer Institute, a typical, spontaneous mutation in blood stem cells, which has been linked to higher risks of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells' programming of gene activity and the variety of blood cells they produce.
Washington [US], August 26 (ANI): A detailed analysis of pancreatic cancer by researchers at Washington University School of Medicine in St. Louis has revealed details of two key transition points in the development of these tumours the shift from normal cells to precancerous cells and the change from precancerous to cancerous cells. Understanding these transitions will help lead to the development of novel therapies.
Washington [US], June 14 (ANI): A research study by the Dana-Farber Cancer Institute sheds light on that mystery, providing clues that may link mutations to epigenetic changes, and may point to potential drug targets to reduce the risk for people born with certain genetic mutations.
\
\
\
\
\
\
\
\
\
\
